Shingles Vaccine Market Size, Share, Growth and Forecast (2026 - 2036)

Shingles Vaccine Market is segmented by Product (Recombinant Zoster Vaccine, Live Attenuated Zoster Vaccine, mRNA Based Vaccines, Protein Subunit Vaccines), Application (Preventive Immunization, Elderly Vaccination Programs, Healthcare Institution Use, Public Health Programs), End Use (Hospitals & Clinics, Pharmaceutical Companies, Government & Public Health Agencies, Elderly Care Facilities), and Region, with forecasts covering the period from 2026 to 2036.

According to Fact.MR estimates, the global shingles vaccine market was valued at USD 5.4 billion in 2025. The market is projected to reach USD 6.3 billion in 2026 and is expected to grow to USD 27.9 billion by 2036, expanding at a CAGR of 16.1%. Recombinant Zoster Vaccine is anticipated to account for 54.0% of the product segment in 2026, while Preventive Immunization is expected to remain the leading application with around 58.0% share.

Free Sample
Download PDF

Shingles Vaccine Market Analysis and Forecast by Fact.MR

  • The global market for shingles vaccines is estimated at US$ 6.27 billion in 2026 and is forecast to expand at a CAGR of 16.1% to reach US$ 27.9 billion by 2036.
  • Shingles vaccines are designed to prevent herpes zoster reactivation in aging populations, using recombinant protein antigens, adjuvant systems, and mRNA platforms to trigger targeted immune responses.
  • Recombinant zoster vaccines currently lead the product landscape, supported by strong clinical efficacy data and regulatory approvals across North America, Europe, and parts of Asia Pacific. The pipeline is expanding with next generation mRNA formulations and protein subunit candidates, which aim to improve thermostability, reduce dosing complexity, and widen access in lower income healthcare settings.
  • As national immunization programs begin incorporating adult shingles vaccination, demand is expected to scale across both private and public healthcare delivery channels globally.

Shingles Vaccine Market Market Value Analysis

Summary of Shingles Vaccine Market

  • Market Snapshot
    • In 2025, the global Shingles Vaccine Market was valued at approximately USD 5.4 billion.
    • The market is estimated to reach USD 6.27 billion in 2026 and is projected to attain USD 27.9 billion by 2036.
    • The shingles vaccine market is likely to expand at a CAGR of 16.1% during the forecast period.
    • The market is anticipated to create an absolute dollar opportunity of USD 21.63 billion between 2026 and 2036.
    • Recombinant Zoster Vaccine accounts for 54% of product share in 2026.
    • Australia (17.4%) and Canada (16.7%) are the key growth markets during the forecast period.
  • Demand and Growth Drivers
    • Aging global population is increasing the eligible patient pool for shingles vaccination, particularly in markets with growing 50 plus demographics.
    • Expansion of national adult immunization programs across Europe, Asia Pacific, and North America is creating new public procurement channels.
    • Strong clinical efficacy data for recombinant zoster vaccines is accelerating regulatory approvals and reimbursement coverage in multiple geographies.
    • Expansion of distribution channels and direct to customer platforms is improving market access and product penetration across geographies.
    • Growing investment in research and product development is supporting the introduction of higher specification and differentiated products.
  • Product and Segment View
    • Recombinant zoster vaccines hold 54% of the product type segment in 2026, supported by strong clinical efficacy data, regulatory approvals across major markets, and established procurement channels in both private and public healthcare settings.
    • Preventive immunization represents 58% of the application segment in 2026, with routine adult vaccination schedules, high risk prevention protocols, and national immunization program expansions acting as the primary demand channels.
    • mRNA based vaccines are growing faster in percentage terms, with their share projected to rise as pipeline candidates advance through clinical trials and regulatory agencies evaluate new formulation platforms for adult immunization.
    • Key segmentation includes:
      • Product: Recombinant Zoster Vaccine, Live Attenuated Zoster Vaccine, mRNA Based Vaccines, Protein Subunit Vaccines
      • Application: Preventive Immunization, Elderly Vaccination Programs, Healthcare Institution Use, Public Health Programs
      • End Use: Hospitals & Clinics, Pharmaceutical Companies, Government & Public Health Agencies, Elderly Care Facilities
      • Technology: Recombinant DNA Technology, Adjuvant Technology, mRNA Vaccine Technology, Viral Vector Technology
      • Formulation: Vaccine Dosage Systems, Delivery Systems, Advanced Formulations, Stability Based Formulations
  • Geography and Competitive Outlook
    • Australia leads growth at 17.4%, supported by expanding domestic demand, industry investment, and favorable policy conditions.
    • North America shows mixed growth patterns, with the United States representing a mature market and Canada showing stronger growth driven by emerging applications.
    • Europe demonstrates steady demand, with Germany and the UK supported by regulatory frameworks and established industrial infrastructure.
    • Key players in this market include GlaxoSmithKline plc. (GSK), Pfizer Inc., Merck & Co. Inc., CanSinoBIO (CanSino Biologics Inc.), Vaccitech plc..
  • Analyst Opinion
    • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The shingles vaccine market is entering a structural growth phase as national immunization programs expand adult vaccination coverage beyond high income markets. Recombinant platforms remain the primary revenue base, but mRNA candidates are advancing toward late stage trials, which could reshape the competitive and pricing landscape within the next five years. The real inflection point will come from reimbursement inclusion in public healthcare budgets across Europe and Asia Pacific, where coverage gaps remain wide despite aging population demographics. Companies that secure early positioning in government tender pipelines and establish cold chain partnerships in mid income markets are likely to capture the next wave of volume growth.'

Key Growth Drivers, Constraints, and Opportunities

Shingles Vaccine Market Opportunity Matrix Growth Vs Value

Key Factors Driving Growth

  • Aging global population is increasing the eligible patient pool for shingles vaccination, particularly in markets with growing 50 plus demographics.
  • Expansion of national adult immunization programs across Europe, Asia Pacific, and North America is creating new public procurement channels.
  • Strong clinical efficacy data for recombinant zoster vaccines is accelerating regulatory approvals and reimbursement coverage in multiple geographies.

Key Market Constraints

  • High per dose cost of recombinant vaccines limits accessibility in price sensitive markets and public health budgets with competing priorities.
  • Cold chain infrastructure gaps in emerging markets restrict distribution reach and storage integrity for temperature sensitive formulations.
  • Low awareness of adult vaccination benefits among general populations and primary care providers slows voluntary uptake outside mandated programs.

Key Opportunity Areas

  • mRNA vaccine platforms entering late stage development could create a new competitive tier with improved thermostability and simplified dosing regimens.
  • Expanding elderly care facility networks in Asia Pacific and Latin America represent underpenetrated institutional demand channels.
  • Government tender pipelines for adult vaccination programs in mid income countries are opening bulk procurement opportunities for established vaccine manufacturers.

Segment-wise Analysis of the Shingles Vaccine Market

  • Recombinant zoster vaccines hold 54% of the product type segment in 2026, supported by strong clinical efficacy data, regulatory approvals across major markets, and established procurement channels in both private and public healthcare settings.
  • Preventive immunization represents 58% of the application segment in 2026, with routine adult vaccination schedules, high risk prevention protocols, and national immunization program expansions acting as the primary demand channels.
  • mRNA based vaccines are growing faster in percentage terms, with their share projected to rise as pipeline candidates advance through clinical trials and regulatory agencies evaluate new formulation platforms for adult immunization.

The shingles vaccine market is segmented by product type, application, end use, technology, and formulation. By product type, the market covers recombinant zoster vaccines, live attenuated zoster vaccines, mRNA based vaccines, and protein subunit vaccines. By application, coverage includes preventive immunization, elderly vaccination programs, healthcare institution use, and public health programs. Recombinant platforms lead by value in the near term because of their demonstrated efficacy and regulatory acceptance, while mRNA candidates are expected to drive the next phase of growth as clinical data matures and production scalability improves.

Which Product Type Segment Dominates the Shingles Vaccine Market?

Shingles Vaccine Market Analysis By Product

Recombinant zoster vaccines account for approximately 54% of the total market value in 2026. Established clinical efficacy profiles, strong regulatory approvals in North America and Europe, and inclusion in national adult immunization schedules are the main sources of support for this leadership. The recombinant platform offers superior long term protection compared to live attenuated alternatives, which continues to drive preference among healthcare providers and procurement agencies.

Recombinant vaccines are firmly positioned across private healthcare and government vaccination channels, where two dose regimens are becoming standard for adults aged 50 and above. Their strong safety data and consistent immune response profiles support adoption across diverse patient populations, including immunocompromised individuals who are not eligible for live vaccine alternatives.

Which Application Segment Dominates the Shingles Vaccine Market?

Shingles Vaccine Market Analysis By Formulation

Preventive immunization is expected to be the dominant application segment with 58% of global market value in 2026. Rising demand is shaped by the growing inclusion of shingles vaccination in routine adult health programs, expansion of high risk prevention protocols, and increased physician awareness of herpes zoster complications in aging populations.

Elderly vaccination programs remain a major application category, but preventive immunization is gaining broader institutional support because it targets a wider age range and integrates with existing healthcare delivery infrastructure. The segment is expected to strengthen its position over the forecast period as more countries add shingles vaccination to their standard adult immunization calendars.

Which Product Trend is Shaping the Next Phase of Growth in the Shingles Vaccine Market?

mRNA based shingles vaccines are not yet commercially dominant, but they are emerging as the fastest developing product category in the pipeline. Multiple candidates are advancing through clinical trials, with formulations that leverage lipid nanoparticle delivery, synthetic mRNA platforms, and self amplifying RNA systems to achieve targeted immune responses with simplified dosing and improved thermostability. This is particularly relevant for expanding vaccination access in markets where cold chain infrastructure remains a constraint.

The shift toward mRNA platforms reflects a broader change in vaccine development priorities. Regulatory agencies are increasingly open to platform based approval pathways, which could accelerate time to market for next generation shingles vaccines. As production scalability improves and clinical efficacy data matures, mRNA candidates could move from a development stage niche into a competitive force against established recombinant products, particularly in price sensitive public health markets.

Regional Outlook Across Key Markets

Top Country Growth Comparison Shingles Vaccine Market Cagr (2026 2036)

  • Australia leads growth at 17.4%, supported by expanding domestic demand and favorable industry conditions.
  • North America shows varied growth, with USA at 15.4% and Canada at 16.7%.
  • European demand remains steady, supported by established industrial infrastructure and regulatory frameworks.

CAGR Table

Country CAGR (%)
Australia 17.4%
Canada 16.7%
France 16.3%
UK 15.6%
USA 15.4%
Germany 15.1%
Japan 14.8%

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Shingles Vaccine Market Cagr Analysis By Country

Market Outlook for Shingles Vaccine in Australia

The Australia shingles vaccine market is projected to grow at a CAGR of 17.4% through 2036.

  • Growing domestic demand supports market expansion.
  • Infrastructure development creates new opportunities.
  • Regulatory environment is evolving to support industry growth.

Demand Trends for Shingles Vaccine in Canada

The Canada shingles vaccine market is projected to grow at a CAGR of 16.7% through 2036.

  • Growing domestic demand supports market expansion.
  • Infrastructure development creates new opportunities.
  • Regulatory environment is evolving to support industry growth.

Growth Assessment for Shingles Vaccine in France

The France shingles vaccine market is projected to grow at a CAGR of 16.3% through 2036.

  • Growing domestic demand supports market expansion.
  • Infrastructure development creates new opportunities.
  • Regulatory environment is evolving to support industry growth.

Market Demand Analysis for Shingles Vaccine in the United Kingdom

The UK shingles vaccine market is projected to grow at a CAGR of 15.6% through 2036.

  • Growing domestic demand supports market expansion.
  • Infrastructure development creates new opportunities.
  • Regulatory environment is evolving to support industry growth.

Growth Outlook for Shingles Vaccine in the United States

Shingles Vaccine Market Country Value Analysis

The USA shingles vaccine market is projected to grow at a CAGR of 15.4% through 2036.

  • Growing domestic demand supports market expansion.
  • Infrastructure development creates new opportunities.
  • Regulatory environment is evolving to support industry growth.

Market Opportunity Outlook for Shingles Vaccine in Germany

The Germany shingles vaccine market is projected to grow at a CAGR of 15.1% through 2036.

  • Growing domestic demand supports market expansion.
  • Infrastructure development creates new opportunities.
  • Regulatory environment is evolving to support industry growth.

Demand Patterns for Shingles Vaccine in Japan

Shingles Vaccine Market Japan Market Share Analysis By Product

The Japan shingles vaccine market is projected to grow at a CAGR of 14.8% through 2036.

  • Growing domestic demand supports market expansion.
  • Infrastructure development creates new opportunities.
  • Regulatory environment is evolving to support industry growth.

Competitive Benchmarking and Company Positioning

Shingles Vaccine Market Analysis By Company

Shingles Vaccine Market Analysis By Company

  • GlaxoSmithKline plc. (GSK), Pfizer Inc., Merck & Co. Inc., CanSinoBIO (CanSino Biologics Inc.) hold strong positions in the global shingles vaccine market through broad product portfolios, established customer relationships, and growing capabilities in their respective technology areas.
  • Vaccitech plc., GC Biopharma Corp., GeneOne Life Science Inc. participate meaningfully across specific price tiers, user segments, and regional channels, with competition shaped by product quality, service capability, and geographic presence.
  • Technology integration and service capabilities create important differentiation factors, especially in segments where product specification and after sales support influence buyer decisions.

The competitive landscape is moderately fragmented, with a mix of established industry leaders, specialized technology providers, and regional players. GlaxoSmithKline plc. (GSK), Pfizer Inc., Merck & Co. Inc. compete through product breadth, technology capabilities, and customer service infrastructure. These companies are positioned to capture value from both new installation demand and aftermarket service requirements.

Competition is shaped by differences in product specification, geographic coverage, and service capability. Companies with integrated product and service offerings, strong distribution networks, and established customer relationships are positioned to retain market share and improve margins over time.

Key Companies in the Shingles Vaccine Market

GlaxoSmithKline plc. (GSK), Pfizer Inc., Merck & Co. Inc., CanSinoBIO (CanSino Biologics Inc.) are among the leading players in the shingles vaccine market globally, supported by strong product portfolios, established market positions, and growing capabilities across key application and geographic segments.

Vaccitech plc., GC Biopharma Corp., GeneOne Life Science Inc. hold established positions across specific customer groups and application areas, supported by product reliability, service capabilities, and category familiarity among end users.

SK bioscience Co. Ltd., AIM Vaccine Co. Ltd., Dynavax Technologies Corporation continue to compete through focused product offerings, price point coverage, and niche strength in specific applications, reinforcing their relevance in a fragmented but evolving market.

Recent Industry Developments

  • GlaxoSmithKline plc. (GSK) Regulatory Expansion / Market Access (2025)
    • GSK secured expanded age based indications for Shingrix in multiple Asia Pacific markets, broadening the eligible vaccination population and strengthening the product's position in government immunization program tenders across the region.
  • Pfizer Inc. Clinical Development / Pipeline Advancement (2025)
    • Pfizer advanced its mRNA based shingles vaccine candidate into Phase 2 clinical trials, targeting improved thermostability and simplified dosing compared to existing recombinant products, with data readouts expected to inform late stage trial design.
  • CanSinoBIO (CanSino Biologics Inc.) Product Launch / Regional Market Entry (2026)
    • CanSinoBIO launched its recombinant shingles vaccine in select domestic and export markets, offering an alternative to GSK's Shingrix platform and expanding competitive options for public health procurement agencies in Asia and the Middle East.

Leading Companies Shaping the Shingles Vaccine Market

  • GlaxoSmithKline plc. (GSK)
  • Pfizer Inc.
  • Merck & Co. Inc.
  • CanSinoBIO (CanSino Biologics Inc.)
  • Vaccitech plc.
  • GC Biopharma Corp.
  • GeneOne Life Science Inc.
  • SK bioscience Co. Ltd.
  • AIM Vaccine Co. Ltd.
  • Dynavax Technologies Corporation

Sources and Research References

  • GlaxoSmithKline plc. (GSK). Product portfolio, corporate announcements, and market disclosures.
  • Pfizer Inc.. Product portfolio, corporate announcements, and market disclosures.
  • Merck & Co. Inc.. Product portfolio, corporate announcements, and market disclosures.
  • Industry association statistics, government agency publications, trade data, customs databases, and company product catalogs.
  • Primary interviews with manufacturers, distributors, end users, and industry specialists.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

  • What is the current and future size of the Shingles Vaccine Market?
  • How fast is the Shingles Vaccine Market expected to grow between 2026 and 2036?
  • Which product type is likely to lead the market by 2026?
  • Which application segment is expected to account for the highest demand by 2026?
  • What factors are driving demand for shingles vaccine globally?
  • Which countries are projected to show the fastest growth through 2036?
  • What is driving market expansion in Australia and Canada?
  • Who are the key companies active in the Shingles Vaccine Market?
  • How does Fact.MR estimate and validate the market forecast?
  • What are the key constraints and opportunity areas in this market?

Shingles Vaccine Market Definition

The shingles vaccine market covers prophylactic vaccines designed to prevent herpes zoster (shingles) reactivation in adult populations, including recombinant, live attenuated, mRNA based, and protein subunit formulations administered through healthcare institutions, public health programs, and elderly care settings.

Shingles Vaccine Market Inclusions

  • The scope covers global and regional market size and forecasts for 2026 to 2036 across product type, application, end use, technology, and formulation.
  • It includes regional demand analysis across major geographies, based on factors such as aging population demographics, immunization program coverage, regulatory approvals, and healthcare infrastructure maturity.
  • The report includes pricing and cost analysis across vaccine types, dosing formats, and distribution channels, covering procurement, storage, and administration costs.
  • It covers technology trends, market drivers and constraints, and the competitive landscape, including product portfolios, clinical pipelines, pricing strategy, and geographic coverage of leading vaccine manufacturers.

Shingles Vaccine Market Exclusions

  • The scope excludes general purpose immunization products not specifically designed for herpes zoster prevention, including broad spectrum antiviral treatments, pain management therapies, and post herpetic neuralgia drugs.
  • It excludes diagnostic tools, testing kits, and laboratory equipment used for shingles detection but not directly tied to vaccination.
  • The report excludes veterinary vaccines, experimental compounds not yet in clinical trials, and informal or unregulated vaccine distribution channels.
  • It also excludes general healthcare infrastructure spending, hospital construction, and public health administration costs not directly tied to shingles vaccination programs.

Shingles Vaccine Market Research Methodology

  • The methodology combines secondary research, primary interviews, and forecast modelling.
  • It draws on 100+ secondary sources and benchmarks 50+ company product portfolios.
  • Market sizing covers 30+ countries through a demand side model, supported by top down validation.
  • Key inputs include industry production data, trade statistics, pricing benchmarks, regulatory frameworks, and end use demand patterns.
  • The model cross checks demand with shipments, pricing trends, channel mix, and product launches.
  • Primary validation includes 20+ interviews across manufacturers, distributors, end users, and industry specialists.
  • Final estimates go through trade flow checks, sales pattern review, and sensitivity testing.

Scope of Analysis

Shingles Vaccine Market Breakdown By Product, Application, And Region

Parameter Details
Quantitative Units USD 6.27 billion to USD 27.9 billion, at a CAGR of 16.1%
Market Definition The shingles vaccine market covers prophylactic vaccines designed to prevent herpes zoster (shingles) reactivation in adult populations, including recombinant, live attenuated, mRNA based, and protein subunit formulations administered through healthcare institutions, public health programs, and elderly care settings.
Regions Covered North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered Australia, Canada, France, UK, USA, Germany, Japan, 30 plus countries
Key Companies GlaxoSmithKline plc. (GSK), Pfizer Inc., Merck & Co. Inc., CanSinoBIO (CanSino Biologics Inc.), Vaccitech plc., GC Biopharma Corp., GeneOne Life Science Inc., SK bioscience Co. Ltd., AIM Vaccine Co. Ltd., Dynavax Technologies Corporation
Forecast Period 2026 to 2036
Approach Hybrid demand side and top down methodology built on country level demand analysis, product benchmarking, pricing analysis, shipment validation, and primary interviews across manufacturers, distributors, and end users

Shingles Vaccine Market Segmentation

  • Shingles Vaccine market Segmented by Product:

    • Recombinant Zoster Vaccine
      • Adjuvanted Recombinant Vaccines
        • Glycoprotein E Subunit Vaccines
        • AS01B Adjuvant Formulations
      • Next Gen Recombinant Platforms
        • Protein Expression Vaccines
        • Immune Enhanced Antigen Systems
    • Live Attenuated Zoster Vaccine
      • Traditional Live Vaccines
        • High Potency Viral Vaccines
        • Cell Culture Derived Vaccines
      • Single Dose Live Formulations
        • Standard Viral Strain Vaccines
        • Attenuated Herpes Zoster Strains
    • mRNA Based Vaccines
      • Lipid Nanoparticle Vaccines
        • Synthetic mRNA Platforms
        • Gene Expression Vaccines
      • Experimental mRNA Formulations
        • Therapeutic mRNA Systems
        • Immune Programming Vaccines
    • Protein Subunit Vaccines
      • Purified Antigen Vaccines
        • Recombinant Protein Antigens
        • Virus Derived Subunits
      • Recombinant Subunit Systems
        • Engineered Protein Platforms
        • Stabilized Antigen Systems

  • Shingles Vaccine market Segmented by Application:

    • Preventive Immunization
      • Routine Adult Vaccination
        • Standard Immunization Schedules
        • Preventive Health Programs
      • High Risk Prevention
        • Immunocompromised Patients
        • Chronic Disease Patients
    • Elderly Vaccination Programs
      • Age Based Immunization
        • 50 Plus Vaccination Programs
        • 65 Plus Vaccination Programs
      • Long Term Care Immunization
        • Nursing Home Vaccination
        • Geriatric Clinic Programs
    • Healthcare Institution Use
      • Hospital Based Immunization
        • Outpatient Vaccination Units
        • Specialty Immunology Clinics
      • Primary Care Settings
        • Family Physician Clinics
        • Community Health Centers
    • Public Health Programs
      • National Immunization Drives
        • Government Vaccination Campaigns
        • Mass Immunization Programs
      • Global Health Initiatives
        • WHO Supported Programs
        • NGO Health Campaigns

  • Shingles Vaccine market Segmented by End Use:

    • Hospitals & Clinics
      • Private Healthcare Facilities
        • Multi Specialty Hospitals
        • Infectious Disease Clinics
      • Public Healthcare Systems
        • Government Hospitals
        • Urban Health Centers
    • Pharmaceutical Companies
      • Vaccine Manufacturers
        • Large Scale Pharma Firms
        • Biotech Vaccine Developers
      • Contract Manufacturing Organizations
        • Fill Finish Providers
        • Vaccine Production CMOs
    • Government & Public Health Agencies
      • National Health Authorities
        • Disease Control Agencies
        • Immunization Departments
      • International Organizations
        • WHO Programs
        • Global Health Agencies
    • Elderly Care Facilities
      • Senior Living Centers
        • Assisted Living Facilities
        • Long Term Care Homes
      • Geriatric Healthcare Units
        • Specialized Elder Care Clinics
        • Preventive Care Units

  • Shingles Vaccine market Segmented by Technology:

    • Recombinant DNA Technology
      • Protein Expression Platforms
        • Bacterial Expression Systems
        • Mammalian Cell Expression
      • Antigen Engineering Systems
        • Glycoprotein Engineering
        • Epitope Optimization Systems
    • Adjuvant Technology
      • Immune Enhancement Systems
        • AS01B Adjuvant Systems
        • Oil in Water Emulsion Systems
      • Cytokine Activation Systems
        • T Cell Activation Enhancers
        • Memory Cell Induction Systems
    • mRNA Vaccine Technology
      • Synthetic mRNA Platforms
        • Lipid Nanoparticle Delivery
        • Self Amplifying mRNA Systems
      • Gene Expression Control
        • RNA Stabilization Systems
        • Targeted Expression Platforms
    • Viral Vector Technology
      • Attenuated Virus Systems
        • Recombinant Viral Vectors
        • Replication Deficient Systems
      • Virus Engineering Platforms
        • Modified Herpes Virus Systems
        • Vector Safety Optimization

  • Shingles Vaccine market Segmented by Formulation:

    • Vaccine Dosage Systems
      • Single Dose Formulations
        • Pre Filled Syringes
        • Ready To Use Vials
      • Multi Dose Formulations
        • Preserved Multi Dose Vials
        • Bulk Immunization Packs
    • Delivery Systems
      • Injectable Formulations
        • Intramuscular Delivery Systems
        • Subcutaneous Delivery Systems
      • Reconstituted Formulations
        • Lyophilized Powder Vaccines
        • Diluent Mixed Vaccines
    • Advanced Formulations
      • Adjuvanted Formulations
        • AS01B Based Vaccines
        • Immune Boost Formulations
      • Recombinant Formulations
        • Protein Engineered Vaccines
        • Antigen Stabilized Systems
    • Stability Based Formulations
      • Cold Chain Dependent Formulations
        • Refrigerated Vaccine Solutions
        • Temperature Controlled Liquids
      • Thermostable Formulations
        • Heat Resistant Vaccines
        • Buffer Stabilized Systems

  • Shingles Vaccine market Segmented by Formulation:

    • Vaccine Dosage Systems
      • Single Dose Formulations
        • Pre Filled Syringes
        • Ready To Use Vials
      • Multi Dose Formulations
        • Preserved Multi Dose Vials
        • Bulk Immunization Packs
    • Delivery Systems
      • Injectable Formulations
        • Intramuscular Delivery Systems
        • Subcutaneous Delivery Systems
      • Reconstituted Formulations
        • Lyophilized Powder Vaccines
        • Diluent Mixed Vaccines
    • Advanced Formulations
      • Adjuvanted Formulations
        • AS01B Based Vaccines
        • Immune Boost Formulations
      • Recombinant Formulations
        • Protein Engineered Vaccines
        • Antigen Stabilized Systems
    • Stability Based Formulations
      • Cold Chain Dependent Formulations
        • Refrigerated Vaccine Solutions
        • Temperature Controlled Liquids
      • Thermostable Formulations
        • Heat Resistant Vaccines
        • Buffer Stabilized Systems

  • Shingles Vaccine market by Region:

    • North America
      • USA
      • Canada
      • Mexico
    • Latin America
      • Brazil
      • Chile
      • Rest of Latin America
    • Western Europe
      • Germany
      • UK
      • Italy
      • Spain
      • France
      • Nordic
      • BENELUX
      • Rest of Western Europe
    • Eastern Europe
      • Russia
      • Poland
      • Hungary
      • Balkan & Baltic
      • Rest of Eastern Europe
    • East Asia
      • China
      • Japan
      • South Korea
    • South Asia and Pacific
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of South Asia and Pacific
    • Middle East & Africa
      • Kingdom of Saudi Arabia
      • Other GCC Countries
      • Turkiye
      • South Africa
      • Other African Union
      • Rest of Middle East & Africa

- Frequently Asked Questions -

How big is the shingles vaccine market in 2025?

The global shingles vaccine market is estimated to be valued at USD 5.4 billion in 2025.

What will be the size of the shingles vaccine market in 2036?

The market size for the shingles vaccine market is projected to reach USD 27.9 billion by 2036.

How much will the shingles vaccine market grow between 2026 and 2036?

The shingles vaccine market is expected to grow at a 16.1% CAGR between 2026 and 2036.

What are the key product types in the shingles vaccine market?

The key product types in the shingles vaccine market are recombinant zoster vaccine, live attenuated zoster vaccine, mrna based vaccines, protein subunit vaccines.

Which segment will contribute significant share in the shingles vaccine market in 2026?

In terms of product, recombinant zoster vaccine is expected to account for 54% share in the shingles vaccine market in 2026.

Which are the fastest growing countries in the shingles vaccine market?

Australia (17.4%) and Canada (16.7%) are the key growth markets during the forecast period.

Table of Content

  1. Executive Summary
    • Global Market Outlook
    • Demand to side Trends
    • Supply to side Trends
    • Technology Roadmap Analysis
    • Analysis and Recommendations
  2. Market Overview
    • Market Coverage / Taxonomy
    • Market Definition / Scope / Limitations
  3. Research Methodology
    • Chapter Orientation
    • Analytical Lens and Working Hypotheses
      • Market Structure, Signals, and Trend Drivers
      • Benchmarking and Cross-market Comparability
      • Market Sizing, Forecasting, and Opportunity Mapping
    • Research Design and Evidence Framework
      • Desk Research Programme (Secondary Evidence)
        • Company Annual and Sustainability Reports
        • Peer-reviewed Journals and Academic Literature
        • Corporate Websites, Product Literature, and Technical Notes
        • Earnings Decks and Investor Briefings
        • Statutory Filings and Regulatory Disclosures
        • Technical White Papers and Standards Notes
        • Trade Journals, Industry Magazines, and Analyst Briefs
        • Conference Proceedings, Webinars, and Seminar Materials
        • Government Statistics Portals and Public Data Releases
        • Press Releases and Reputable Media Coverage
        • Specialist Newsletters and Curated Briefings
        • Sector Databases and Reference Repositories
        • Fact.MR Internal Proprietary Databases and Historical Market Datasets
        • Subscription Datasets and Paid Sources
        • Social Channels, Communities, and Digital Listening Inputs
        • Additional Desk Sources
      • Expert Input and Fieldwork (Primary Evidence)
        • Primary Modes
          • Qualitative Interviews and Expert Elicitation
          • Quantitative Surveys and Structured Data Capture
          • Blended Approach
        • Why Primary Evidence is Used
        • Field Techniques
          • Interviews
          • Surveys
          • Focus Groups
          • Observational and In-context Research
          • Social and Community Interactions
        • Stakeholder Universe Engaged
          • C-suite Leaders
          • Board Members
          • Presidents and Vice Presidents
          • R&D and Innovation Heads
          • Technical Specialists
          • Domain Subject-matter Experts
          • Scientists
          • Physicians and Other Healthcare Professionals
        • Governance, Ethics, and Data Stewardship
          • Research Ethics
          • Data Integrity and Handling
      • Tooling, Models, and Reference Databases
    • Data Engineering and Model Build
      • Data Acquisition and Ingestion
      • Cleaning, Normalisation, and Verification
      • Synthesis, Triangulation, and Analysis
    • Quality Assurance and Audit Trail
  4. Market Background
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
      • Trends
    • Scenario Forecast
      • Demand in Optimistic Scenario
      • Demand in Likely Scenario
      • Demand in Conservative Scenario
    • Opportunity Map Analysis
    • Product Life Cycle Analysis
    • Supply Chain Analysis
    • Investment Feasibility Matrix
    • Value Chain Analysis
    • PESTLE and Porter’s Analysis
    • Regulatory Landscape
    • Regional Parent Market Outlook
    • Production and Consumption Statistics
    • Import and Export Statistics
  5. Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
    • Historical Market Size Value (USD Million) Analysis, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
      • Y to o to Y Growth Trend Analysis
      • Absolute $ Opportunity Analysis
  6. Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
  7. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Product
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Product, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Product, 2026 to 2036
      • Recombinant Zoster Vaccine
        • Adjuvanted Recombinant Vaccines
        • Glycoprotein E Subunit Vaccines
        • AS01B Adjuvant Formulations
        • Next Gen Recombinant Platforms
        • Protein Expression Vaccines
        • Immune Enhanced Antigen Systems
      • Live Attenuated Zoster Vaccine
        • Traditional Live Vaccines
        • High Potency Viral Vaccines
        • Cell Culture Derived Vaccines
        • Single Dose Live Formulations
        • Standard Viral Strain Vaccines
      • mRNA Based Vaccines
        • Lipid Nanoparticle Vaccines
        • Synthetic mRNA Platforms
        • Gene Expression Vaccines
        • Experimental mRNA Formulations
        • Therapeutic mRNA Systems
      • Protein Subunit Vaccines
        • Purified Antigen Vaccines
        • Recombinant Protein Antigens
        • Virus Derived Subunits
        • Recombinant Subunit Systems
        • Engineered Protein Platforms
    • Y to o to Y Growth Trend Analysis By Product, 2021 to 2025
    • Absolute $ Opportunity Analysis By Product, 2026 to 2036
  8. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Application
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Application, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Application, 2026 to 2036
      • Preventive Immunization
        • Routine Adult Vaccination
        • Standard Immunization Schedules
        • Preventive Health Programs
        • High Risk Prevention
        • Immunocompromised Patients
        • Chronic Disease Patients
      • Elderly Vaccination Programs
        • Age Based Immunization
        • 50 Plus Vaccination Programs
        • 65 Plus Vaccination Programs
        • Long Term Care Immunization
        • Nursing Home Vaccination
      • Healthcare Institution Use
        • Hospital Based Immunization
        • Outpatient Vaccination Value (USD Million)s
        • Specialty Immunology Clinics
        • Primary Care Settings
        • Family Physician Clinics
      • Public Health Programs
        • National Immunization Drives
        • Government Vaccination Campaigns
        • Mass Immunization Programs
        • Global Health Initiatives
        • WHO Supported Programs
    • Y to o to Y Growth Trend Analysis By Application, 2021 to 2025
    • Absolute $ Opportunity Analysis By Application, 2026 to 2036
  9. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By End Use
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By End Use, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By End Use, 2026 to 2036
      • Hospitals & Clinics
        • Private Healthcare Facilities
        • Multi Specialty Hospitals
        • Infectious Disease Clinics
        • Public Healthcare Systems
        • Government Hospitals
        • Urban Health Centers
      • Pharmaceutical Companies
        • Vaccine Manufacturers
        • Large Scale Pharma Firms
        • Biotech Vaccine Developers
        • Contract Manufacturing Organizations
        • Fill Finish Providers
      • Government & Public Health Agencies
        • National Health Authorities
        • Disease Control Agencies
        • Immunization Departments
        • International Organizations
        • WHO Programs
      • Elderly Care Facilities
        • Senior Living Centers
        • Assisted Living Facilities
        • Long Term Care Homes
        • Geriatric Healthcare Value (USD Million)s
        • Specialized Elder Care Clinics
    • Y to o to Y Growth Trend Analysis By End Use, 2021 to 2025
    • Absolute $ Opportunity Analysis By End Use, 2026 to 2036
  10. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Technology
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Technology, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Technology, 2026 to 2036
      • Recombinant DNA Technology
        • Protein Expression Platforms
        • Bacterial Expression Systems
        • Mammalian Cell Expression
        • Antigen Engineering Systems
        • Glycoprotein Engineering
        • Epitope Optimization Systems
      • Adjuvant Technology
        • Immune Enhancement Systems
        • AS01B Adjuvant Systems
        • Oil in Water Emulsion Systems
        • Cytokine Activation Systems
        • T Cell Activation Enhancers
      • mRNA Vaccine Technology
        • Synthetic mRNA Platforms
        • Lipid Nanoparticle Delivery
        • Self Amplifying mRNA Systems
        • Gene Expression Control
        • RNA Stabilization Systems
      • Viral Vector Technology
        • Attenuated Virus Systems
        • Recombinant Viral Vectors
        • Replication Deficient Systems
        • Virus Engineering Platforms
        • Modified Herpes Virus Systems
    • Y to o to Y Growth Trend Analysis By Technology, 2021 to 2025
    • Absolute $ Opportunity Analysis By Technology, 2026 to 2036
  11. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Formulation
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Formulation, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Formulation, 2026 to 2036
      • Vaccine Dosage Systems
        • Single Dose Formulations
        • Pre Filled Syringes
        • Ready To Use Vials
        • Multi Dose Formulations
        • Preserved Multi Dose Vials
        • Bulk Immunization Packs
      • Delivery Systems
        • Injectable Formulations
        • Intramuscular Delivery Systems
        • Subcutaneous Delivery Systems
        • Reconstituted Formulations
        • Lyophilized Powder Vaccines
      • Advanced Formulations
        • Adjuvanted Formulations
        • AS01B Based Vaccines
        • Immune Boost Formulations
        • Recombinant Formulations
        • Protein Engineered Vaccines
      • Stability Based Formulations
        • Cold Chain Dependent Formulations
        • Refrigerated Vaccine Solutions
        • Temperature Controlled Liquids
        • Thermostable Formulations
        • Heat Resistant Vaccines
    • Y to o to Y Growth Trend Analysis By Formulation, 2021 to 2025
    • Absolute $ Opportunity Analysis By Formulation, 2026 to 2036
  12. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Formulation
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Formulation, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Formulation, 2026 to 2036
      • Vaccine Dosage Systems
        • Single Dose Formulations
        • Pre Filled Syringes
        • Ready To Use Vials
        • Multi Dose Formulations
        • Preserved Multi Dose Vials
        • Bulk Immunization Packs
      • Delivery Systems
        • Injectable Formulations
        • Intramuscular Delivery Systems
        • Subcutaneous Delivery Systems
        • Reconstituted Formulations
        • Lyophilized Powder Vaccines
      • Advanced Formulations
        • Adjuvanted Formulations
        • AS01B Based Vaccines
        • Immune Boost Formulations
        • Recombinant Formulations
        • Protein Engineered Vaccines
      • Stability Based Formulations
        • Cold Chain Dependent Formulations
        • Refrigerated Vaccine Solutions
        • Temperature Controlled Liquids
        • Thermostable Formulations
        • Heat Resistant Vaccines
    • Y to o to Y Growth Trend Analysis By Formulation, 2021 to 2025
    • Absolute $ Opportunity Analysis By Formulation, 2026 to 2036
  13. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
    • Introduction
    • Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
    • Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
      • North America
      • Latin America
      • Western Europe
      • Eastern Europe
      • East Asia
      • South Asia and Pacific
      • Middle East & Africa
    • Market Attractiveness Analysis By Region
  14. North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • USA
        • Canada
        • Mexico
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Market Attractiveness Analysis
      • By Country
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Key Takeaways
  15. Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Brazil
        • Chile
        • Rest of Latin America
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Market Attractiveness Analysis
      • By Country
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Key Takeaways
  16. Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Germany
        • UK
        • Italy
        • Spain
        • France
        • Nordic
        • BENELUX
        • Rest of Western Europe
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Market Attractiveness Analysis
      • By Country
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Key Takeaways
  17. Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Russia
        • Poland
        • Hungary
        • Balkan & Baltic
        • Rest of Eastern Europe
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Market Attractiveness Analysis
      • By Country
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Key Takeaways
  18. East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • China
        • Japan
        • South Korea
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Market Attractiveness Analysis
      • By Country
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Key Takeaways
  19. South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • India
        • ASEAN
        • Australia & New Zealand
        • Rest of South Asia and Pacific
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Market Attractiveness Analysis
      • By Country
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Key Takeaways
  20. Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Kingdom of Saudi Arabia
        • Other GCC Countries
        • Turkiye
        • South Africa
        • Other African Union
        • Rest of Middle East & Africa
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Market Attractiveness Analysis
      • By Country
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
    • Key Takeaways
  21. Key Countries Market Analysis
    • USA
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Canada
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Mexico
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Brazil
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Chile
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Germany
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • UK
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Italy
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Spain
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • France
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • India
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • ASEAN
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Australia & New Zealand
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • China
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Japan
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • South Korea
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Russia
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Poland
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Hungary
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Kingdom of Saudi Arabia
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • Turkiye
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
    • South Africa
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Product
        • By Application
        • By End Use
        • By Technology
        • By Formulation
        • By Formulation
  22. Market Structure Analysis
    • Competition Dashboard
    • Competition Benchmarking
    • Market Share Analysis of Top Players
      • By Regional
      • By Product
      • By Application
      • By End Use
      • By Technology
      • By Formulation
      • By Formulation
  23. Competition Analysis
    • Competition Deep Dive
      • GlaxoSmithKline plc. (GSK)
        • Overview
        • Product Portfolio
        • Profitability by Market Segments (Product/Age /Sales Channel/Region)
        • Sales Footprint
        • Strategy Overview
          • Marketing Strategy
          • Product Strategy
          • Channel Strategy
      • Pfizer Inc.
      • Merck & Co. Inc.
      • CanSinoBIO (CanSino Biologics Inc.)
      • Vaccitech plc.
      • GC Biopharma Corp.
      • GeneOne Life Science Inc.
      • SK bioscience Co. Ltd.
      • AIM Vaccine Co. Ltd.
      • Dynavax Technologies Corporation
  24. Assumptions & Acronyms Used

List Of Table

  • Table 1: Global Market Value (USD Million) Forecast by Region, 2021 to 2036
  • Table 2: Global Market Value (USD Million) Forecast by Product, 2021 to 2036
  • Table 3: Global Market Value (USD Million) Forecast by Application, 2021 to 2036
  • Table 4: Global Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 5: Global Market Value (USD Million) Forecast by Technology, 2021 to 2036
  • Table 6: Global Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 7: Global Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 8: North America Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 9: North America Market Value (USD Million) Forecast by Product, 2021 to 2036
  • Table 10: North America Market Value (USD Million) Forecast by Application, 2021 to 2036
  • Table 11: North America Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 12: North America Market Value (USD Million) Forecast by Technology, 2021 to 2036
  • Table 13: North America Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 14: North America Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 15: Latin America Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 16: Latin America Market Value (USD Million) Forecast by Product, 2021 to 2036
  • Table 17: Latin America Market Value (USD Million) Forecast by Application, 2021 to 2036
  • Table 18: Latin America Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 19: Latin America Market Value (USD Million) Forecast by Technology, 2021 to 2036
  • Table 20: Latin America Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 21: Latin America Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 22: Western Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 23: Western Europe Market Value (USD Million) Forecast by Product, 2021 to 2036
  • Table 24: Western Europe Market Value (USD Million) Forecast by Application, 2021 to 2036
  • Table 25: Western Europe Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 26: Western Europe Market Value (USD Million) Forecast by Technology, 2021 to 2036
  • Table 27: Western Europe Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 28: Western Europe Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 29: Eastern Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 30: Eastern Europe Market Value (USD Million) Forecast by Product, 2021 to 2036
  • Table 31: Eastern Europe Market Value (USD Million) Forecast by Application, 2021 to 2036
  • Table 32: Eastern Europe Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 33: Eastern Europe Market Value (USD Million) Forecast by Technology, 2021 to 2036
  • Table 34: Eastern Europe Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 35: Eastern Europe Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 36: East Asia Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 37: East Asia Market Value (USD Million) Forecast by Product, 2021 to 2036
  • Table 38: East Asia Market Value (USD Million) Forecast by Application, 2021 to 2036
  • Table 39: East Asia Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 40: East Asia Market Value (USD Million) Forecast by Technology, 2021 to 2036
  • Table 41: East Asia Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 42: East Asia Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 43: South Asia and Pacific Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 44: South Asia and Pacific Market Value (USD Million) Forecast by Product, 2021 to 2036
  • Table 45: South Asia and Pacific Market Value (USD Million) Forecast by Application, 2021 to 2036
  • Table 46: South Asia and Pacific Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 47: South Asia and Pacific Market Value (USD Million) Forecast by Technology, 2021 to 2036
  • Table 48: South Asia and Pacific Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 49: South Asia and Pacific Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 50: Middle East & Africa Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 51: Middle East & Africa Market Value (USD Million) Forecast by Product, 2021 to 2036
  • Table 52: Middle East & Africa Market Value (USD Million) Forecast by Application, 2021 to 2036
  • Table 53: Middle East & Africa Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 54: Middle East & Africa Market Value (USD Million) Forecast by Technology, 2021 to 2036
  • Table 55: Middle East & Africa Market Value (USD Million) Forecast by Formulation, 2021 to 2036
  • Table 56: Middle East & Africa Market Value (USD Million) Forecast by Formulation, 2021 to 2036

List Of Figures

  • Figure 1: Global Market Pricing Analysis
  • Figure 2: Global Market Value (USD Million) Forecast 2021 to 2036
  • Figure 3: Global Market Value Share and BPS Analysis by Product, 2026 and 2036
  • Figure 4: Global Market Y-o-Y Growth Comparison by Product, 2026 to 2036
  • Figure 5: Global Market Attractiveness Analysis by Product
  • Figure 6: Global Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 7: Global Market Y-o-Y Growth Comparison by Application, 2026 to 2036
  • Figure 8: Global Market Attractiveness Analysis by Application
  • Figure 9: Global Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 10: Global Market Y-o-Y Growth Comparison by End Use, 2026 to 2036
  • Figure 11: Global Market Attractiveness Analysis by End Use
  • Figure 12: Global Market Value Share and BPS Analysis by Technology, 2026 and 2036
  • Figure 13: Global Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
  • Figure 14: Global Market Attractiveness Analysis by Technology
  • Figure 15: Global Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 16: Global Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 17: Global Market Attractiveness Analysis by Formulation
  • Figure 18: Global Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 19: Global Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 20: Global Market Attractiveness Analysis by Formulation
  • Figure 21: Global Market Value (USD Million) Share and BPS Analysis by Region, 2026 and 2036
  • Figure 22: Global Market Y-o-Y Growth Comparison by Region, 2026 to 2036
  • Figure 23: Global Market Attractiveness Analysis by Region
  • Figure 24: North America Market Incremental Dollar Opportunity, 2026 to 2036
  • Figure 25: Latin America Market Incremental Dollar Opportunity, 2026 to 2036
  • Figure 26: Western Europe Market Incremental Dollar Opportunity, 2026 to 2036
  • Figure 27: Eastern Europe Market Incremental Dollar Opportunity, 2026 to 2036
  • Figure 28: East Asia Market Incremental Dollar Opportunity, 2026 to 2036
  • Figure 29: South Asia and Pacific Market Incremental Dollar Opportunity, 2026 to 2036
  • Figure 30: Middle East & Africa Market Incremental Dollar Opportunity, 2026 to 2036
  • Figure 31: North America Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 32: North America Market Value Share and BPS Analysis by Product, 2026 and 2036
  • Figure 33: North America Market Y-o-Y Growth Comparison by Product, 2026 to 2036
  • Figure 34: North America Market Attractiveness Analysis by Product
  • Figure 35: North America Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 36: North America Market Y-o-Y Growth Comparison by Application, 2026 to 2036
  • Figure 37: North America Market Attractiveness Analysis by Application
  • Figure 38: North America Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 39: North America Market Y-o-Y Growth Comparison by End Use, 2026 to 2036
  • Figure 40: North America Market Attractiveness Analysis by End Use
  • Figure 41: North America Market Value Share and BPS Analysis by Technology, 2026 and 2036
  • Figure 42: North America Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
  • Figure 43: North America Market Attractiveness Analysis by Technology
  • Figure 44: North America Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 45: North America Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 46: North America Market Attractiveness Analysis by Formulation
  • Figure 47: North America Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 48: North America Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 49: North America Market Attractiveness Analysis by Formulation
  • Figure 50: Latin America Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 51: Latin America Market Value Share and BPS Analysis by Product, 2026 and 2036
  • Figure 52: Latin America Market Y-o-Y Growth Comparison by Product, 2026 to 2036
  • Figure 53: Latin America Market Attractiveness Analysis by Product
  • Figure 54: Latin America Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 55: Latin America Market Y-o-Y Growth Comparison by Application, 2026 to 2036
  • Figure 56: Latin America Market Attractiveness Analysis by Application
  • Figure 57: Latin America Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 58: Latin America Market Y-o-Y Growth Comparison by End Use, 2026 to 2036
  • Figure 59: Latin America Market Attractiveness Analysis by End Use
  • Figure 60: Latin America Market Value Share and BPS Analysis by Technology, 2026 and 2036
  • Figure 61: Latin America Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
  • Figure 62: Latin America Market Attractiveness Analysis by Technology
  • Figure 63: Latin America Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 64: Latin America Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 65: Latin America Market Attractiveness Analysis by Formulation
  • Figure 66: Latin America Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 67: Latin America Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 68: Latin America Market Attractiveness Analysis by Formulation
  • Figure 69: Western Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 70: Western Europe Market Value Share and BPS Analysis by Product, 2026 and 2036
  • Figure 71: Western Europe Market Y-o-Y Growth Comparison by Product, 2026 to 2036
  • Figure 72: Western Europe Market Attractiveness Analysis by Product
  • Figure 73: Western Europe Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 74: Western Europe Market Y-o-Y Growth Comparison by Application, 2026 to 2036
  • Figure 75: Western Europe Market Attractiveness Analysis by Application
  • Figure 76: Western Europe Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 77: Western Europe Market Y-o-Y Growth Comparison by End Use, 2026 to 2036
  • Figure 78: Western Europe Market Attractiveness Analysis by End Use
  • Figure 79: Western Europe Market Value Share and BPS Analysis by Technology, 2026 and 2036
  • Figure 80: Western Europe Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
  • Figure 81: Western Europe Market Attractiveness Analysis by Technology
  • Figure 82: Western Europe Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 83: Western Europe Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 84: Western Europe Market Attractiveness Analysis by Formulation
  • Figure 85: Western Europe Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 86: Western Europe Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 87: Western Europe Market Attractiveness Analysis by Formulation
  • Figure 88: Eastern Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 89: Eastern Europe Market Value Share and BPS Analysis by Product, 2026 and 2036
  • Figure 90: Eastern Europe Market Y-o-Y Growth Comparison by Product, 2026 to 2036
  • Figure 91: Eastern Europe Market Attractiveness Analysis by Product
  • Figure 92: Eastern Europe Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 93: Eastern Europe Market Y-o-Y Growth Comparison by Application, 2026 to 2036
  • Figure 94: Eastern Europe Market Attractiveness Analysis by Application
  • Figure 95: Eastern Europe Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 96: Eastern Europe Market Y-o-Y Growth Comparison by End Use, 2026 to 2036
  • Figure 97: Eastern Europe Market Attractiveness Analysis by End Use
  • Figure 98: Eastern Europe Market Value Share and BPS Analysis by Technology, 2026 and 2036
  • Figure 99: Eastern Europe Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
  • Figure 100: Eastern Europe Market Attractiveness Analysis by Technology
  • Figure 101: Eastern Europe Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 102: Eastern Europe Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 103: Eastern Europe Market Attractiveness Analysis by Formulation
  • Figure 104: Eastern Europe Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 105: Eastern Europe Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 106: Eastern Europe Market Attractiveness Analysis by Formulation
  • Figure 107: East Asia Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 108: East Asia Market Value Share and BPS Analysis by Product, 2026 and 2036
  • Figure 109: East Asia Market Y-o-Y Growth Comparison by Product, 2026 to 2036
  • Figure 110: East Asia Market Attractiveness Analysis by Product
  • Figure 111: East Asia Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 112: East Asia Market Y-o-Y Growth Comparison by Application, 2026 to 2036
  • Figure 113: East Asia Market Attractiveness Analysis by Application
  • Figure 114: East Asia Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 115: East Asia Market Y-o-Y Growth Comparison by End Use, 2026 to 2036
  • Figure 116: East Asia Market Attractiveness Analysis by End Use
  • Figure 117: East Asia Market Value Share and BPS Analysis by Technology, 2026 and 2036
  • Figure 118: East Asia Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
  • Figure 119: East Asia Market Attractiveness Analysis by Technology
  • Figure 120: East Asia Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 121: East Asia Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 122: East Asia Market Attractiveness Analysis by Formulation
  • Figure 123: East Asia Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 124: East Asia Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 125: East Asia Market Attractiveness Analysis by Formulation
  • Figure 126: South Asia and Pacific Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 127: South Asia and Pacific Market Value Share and BPS Analysis by Product, 2026 and 2036
  • Figure 128: South Asia and Pacific Market Y-o-Y Growth Comparison by Product, 2026 to 2036
  • Figure 129: South Asia and Pacific Market Attractiveness Analysis by Product
  • Figure 130: South Asia and Pacific Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 131: South Asia and Pacific Market Y-o-Y Growth Comparison by Application, 2026 to 2036
  • Figure 132: South Asia and Pacific Market Attractiveness Analysis by Application
  • Figure 133: South Asia and Pacific Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 134: South Asia and Pacific Market Y-o-Y Growth Comparison by End Use, 2026 to 2036
  • Figure 135: South Asia and Pacific Market Attractiveness Analysis by End Use
  • Figure 136: South Asia and Pacific Market Value Share and BPS Analysis by Technology, 2026 and 2036
  • Figure 137: South Asia and Pacific Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
  • Figure 138: South Asia and Pacific Market Attractiveness Analysis by Technology
  • Figure 139: South Asia and Pacific Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 140: South Asia and Pacific Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 141: South Asia and Pacific Market Attractiveness Analysis by Formulation
  • Figure 142: South Asia and Pacific Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 143: South Asia and Pacific Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 144: South Asia and Pacific Market Attractiveness Analysis by Formulation
  • Figure 145: Middle East & Africa Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 146: Middle East & Africa Market Value Share and BPS Analysis by Product, 2026 and 2036
  • Figure 147: Middle East & Africa Market Y-o-Y Growth Comparison by Product, 2026 to 2036
  • Figure 148: Middle East & Africa Market Attractiveness Analysis by Product
  • Figure 149: Middle East & Africa Market Value Share and BPS Analysis by Application, 2026 and 2036
  • Figure 150: Middle East & Africa Market Y-o-Y Growth Comparison by Application, 2026 to 2036
  • Figure 151: Middle East & Africa Market Attractiveness Analysis by Application
  • Figure 152: Middle East & Africa Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 153: Middle East & Africa Market Y-o-Y Growth Comparison by End Use, 2026 to 2036
  • Figure 154: Middle East & Africa Market Attractiveness Analysis by End Use
  • Figure 155: Middle East & Africa Market Value Share and BPS Analysis by Technology, 2026 and 2036
  • Figure 156: Middle East & Africa Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
  • Figure 157: Middle East & Africa Market Attractiveness Analysis by Technology
  • Figure 158: Middle East & Africa Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 159: Middle East & Africa Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 160: Middle East & Africa Market Attractiveness Analysis by Formulation
  • Figure 161: Middle East & Africa Market Value Share and BPS Analysis by Formulation, 2026 and 2036
  • Figure 162: Middle East & Africa Market Y-o-Y Growth Comparison by Formulation, 2026 to 2036
  • Figure 163: Middle East & Africa Market Attractiveness Analysis by Formulation
  • Figure 164: Global Market - Tier Structure Analysis
  • Figure 165: Global Market - Company Share Analysis
Related Reports

Related Reports

Shingles Vaccine Market

Copyright © Fact.MR All Rights Reserved

An initiative of Eminent Research and Advisory Services